BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, June 5, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 27, 2018
View Archived Issues
Akero Therapeutics closes series A financing to advance development of AKR-001
Read More
aTyr Pharma presents positive phase I results for ATYR-1923
Read More
Prespecified efficacy endpoint met in phase II study of bemcentinib plus Keytruda in NSCLC
Read More
CHMP adopts positive trend vote recommending the approval of the MAA for neratinib
Read More
AD and ID
Read More
Navitor Pharmaceuticals initiates phase I trial of NV-5138 for treatment-resistant depression
Read More
Safety and immunogenicity of ZMapp antibody cocktail for Ebola virus tested in healthy adults
Read More
First-in-human data reported for AMV-564 in patients with relapsed/refractory AML
Read More
Stemline Therapeutics completes rolling BLA submission to the FDA for Elzonris
Read More
Phase II results for CLT-008 in patients receiving AML induction therapy
Read More
Increasing the sensitivity of mu-opioid receptors
Read More
Enteris reports results from final arm of phase IIa trial of Ovarest
Read More
Safety and efficacy of anti-PD-1 antibody SHR-1210 plus apatinib in refractory HCC, GC and EGJC
Read More
Phase II trial evaluates antimalarial activity of single-dose DSM-265
Read More
FDA approves Zemdri for cUTI, but issues CRL for bloodstream infections
Read More
In vivo evaluation of PD-L1-targeted PET imaging agent [64Cu]DK222
Read More
Chugai describes OWL-833, an orally active non-peptide GLP-1 receptor agonist
Read More
Apellis initiates phase III trial of APL-2 in PNH
Read More
Arcus Biosciences, Infinity Pharmaceuticals collaborate on studies of triple combination therapies
Read More
Fraunhofer-Gesellschaft describes new bacterial glutaminyl cyclase inhibitors
Read More
Ensemble Therapeutics divulges IDO-1 inhibitors
Read More
Aclaris initiates phase II trial of ATI-501 for alopecia totalis and alopecia universalis
Read More
Pivot plans IND filing to begin clinical trials with PVT-005
Read More
FDA advisory committees recommend against approval of Remoxy ER
Read More
Servier and Galapagos initiate phase II trial with S-201086 in osteoarthritis
Read More
ThromboGenics plans to change name to Oxurion
Read More
Summit discontinues development of ezutromid based on results of PhaseOut DMD trial
Read More
Phase III trial of rosiptor in interstitial cystitis/bladder pain syndrome misses primary endpoint
Read More
